SE9502244D0 - A composition and a process for the preparation thereof - Google Patents

A composition and a process for the preparation thereof

Info

Publication number
SE9502244D0
SE9502244D0 SE9502244A SE9502244A SE9502244D0 SE 9502244 D0 SE9502244 D0 SE 9502244D0 SE 9502244 A SE9502244 A SE 9502244A SE 9502244 A SE9502244 A SE 9502244A SE 9502244 D0 SE9502244 D0 SE 9502244D0
Authority
SE
Sweden
Prior art keywords
composition
pct
glass
active agent
plasticizer
Prior art date
Application number
SE9502244A
Other languages
English (en)
Inventor
Aake Lindahl
Original Assignee
Bioglan Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioglan Ab filed Critical Bioglan Ab
Priority to SE9502244A priority Critical patent/SE9502244D0/sv
Publication of SE9502244D0 publication Critical patent/SE9502244D0/sv
Priority to PCT/SE1996/000806 priority patent/WO1997000670A1/en
Priority to US08/973,902 priority patent/US6083518A/en
Priority to PT96921197T priority patent/PT833611E/pt
Priority to AT96921197T priority patent/ATE204466T1/de
Priority to CA002225286A priority patent/CA2225286C/en
Priority to AU62473/96A priority patent/AU695622B2/en
Priority to DK96921197T priority patent/DK0833611T3/da
Priority to JP50378997A priority patent/JP4020331B2/ja
Priority to ES96921197T priority patent/ES2118677T3/es
Priority to EP96921197A priority patent/EP0833611B1/en
Priority to DE69614689T priority patent/DE69614689T2/de
Priority to NZ311208A priority patent/NZ311208A/xx
Priority to DE0833611T priority patent/DE833611T1/de
Priority to ZA965237A priority patent/ZA965237B/xx
Priority to HK98109537A priority patent/HK1008774A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/02Suppositories; Bougies; Bases therefor; Ovules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
SE9502244A 1995-06-20 1995-06-20 A composition and a process for the preparation thereof SE9502244D0 (sv)

Priority Applications (16)

Application Number Priority Date Filing Date Title
SE9502244A SE9502244D0 (sv) 1995-06-20 1995-06-20 A composition and a process for the preparation thereof
DE0833611T DE833611T1 (de) 1995-06-20 1996-06-19 Zusammensetzung, die ein in einem glasbildenden träger gelösten wirkstoff enthalt und ein verfahren zu deren herstellung
AU62473/96A AU695622B2 (en) 1995-06-20 1996-06-19 A composition comprising an active agent dissolved in a glass-forming carrier and a process for the preparation thereof
JP50378997A JP4020331B2 (ja) 1995-06-20 1996-06-19 ガラス形成性担体に溶解した活性物質からなる組成物及びその製造方法
PT96921197T PT833611E (pt) 1995-06-20 1996-06-19 Composicao que compreendendo um agente activo dissolvido num veiculo formador de vidro e processo para a sua preparacao
AT96921197T ATE204466T1 (de) 1995-06-20 1996-06-19 Zusammensetzung, die ein in einem glasbildenden träger gelösten wirkstoff enthalt und ein verfahren zu deren herstellung
CA002225286A CA2225286C (en) 1995-06-20 1996-06-19 A composition comprising an active agent dissolved in a glass-forming carrier and a process for the preparation thereof
PCT/SE1996/000806 WO1997000670A1 (en) 1995-06-20 1996-06-19 A composition comprising an active agent dissolved in a glass-forming carrier and a process for the preparation thereof
DK96921197T DK0833611T3 (da) 1995-06-20 1996-06-19 Sammensætning omfattende et aktivt middel opløst i en glasdannende bærer og fremgangsmåde til fremstilling heraf
US08/973,902 US6083518A (en) 1995-06-20 1996-06-19 Composition comprising an active agent dissolved in a glass-forming carrier and a process for the preparation thereof
ES96921197T ES2118677T3 (es) 1995-06-20 1996-06-19 Una composicion que comprende un agente activo disuelto en un vehiculo formador de vidrio y un procedimiento para su preparacion.
EP96921197A EP0833611B1 (en) 1995-06-20 1996-06-19 A composition comprising an active agent dissolved in a glass-forming carrier and a process for the preparation thereof
DE69614689T DE69614689T2 (de) 1995-06-20 1996-06-19 Zusammensetzung, die ein in einem glasbildenden träger gelösten wirkstoff enthalt und ein verfahren zu deren herstellung
NZ311208A NZ311208A (en) 1995-06-20 1996-06-19 Composition comprising an active agent dissolved in a glass-forming carrier comprising a glass-forming substance containing a plasticizer, composition is liquid or jelly-like below 50 degrees
ZA965237A ZA965237B (en) 1995-06-20 1996-06-20 A composition and a process for the preparation thereof
HK98109537A HK1008774A1 (en) 1995-06-20 1998-07-29 A composition comprising an active agent dissolved in a glass-forming carrier and a process for the preparation thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9502244A SE9502244D0 (sv) 1995-06-20 1995-06-20 A composition and a process for the preparation thereof

Publications (1)

Publication Number Publication Date
SE9502244D0 true SE9502244D0 (sv) 1995-06-20

Family

ID=20398685

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9502244A SE9502244D0 (sv) 1995-06-20 1995-06-20 A composition and a process for the preparation thereof

Country Status (15)

Country Link
US (1) US6083518A (sv)
EP (1) EP0833611B1 (sv)
JP (1) JP4020331B2 (sv)
AT (1) ATE204466T1 (sv)
AU (1) AU695622B2 (sv)
CA (1) CA2225286C (sv)
DE (2) DE69614689T2 (sv)
DK (1) DK0833611T3 (sv)
ES (1) ES2118677T3 (sv)
HK (1) HK1008774A1 (sv)
NZ (1) NZ311208A (sv)
PT (1) PT833611E (sv)
SE (1) SE9502244D0 (sv)
WO (1) WO1997000670A1 (sv)
ZA (1) ZA965237B (sv)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136814A (en) * 1997-12-08 2000-10-24 Fujisawa Usa, Inc. Aqueous acyclovir product
SE9801705D0 (sv) * 1998-05-14 1998-05-14 Bioglan Ab Biologically active composition
SE9801704D0 (sv) * 1998-05-14 1998-05-14 Bioglan Ab Biologically active composition
AU7604400A (en) * 1999-09-21 2001-04-24 Emory University Methods and compositions for treating platelet-related disorders using mpl pathway inhibitory agents
CA2359945C (en) * 1999-11-12 2011-04-26 Abbott Laboratories Inhibitors of crystallization in a solid dispersion
US7364752B1 (en) 1999-11-12 2008-04-29 Abbott Laboratories Solid dispersion pharamaceutical formulations
DE10026698A1 (de) * 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
JP4512700B2 (ja) * 2003-06-02 2010-07-28 トーアエイヨー株式会社 アシクロビル含有水溶液製剤
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) * 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US20050101605A1 (en) * 2003-11-07 2005-05-12 Ahmed Salah U. Oral liquid formulations of methotrexate
NZ550119A (en) 2004-04-08 2009-10-30 Biomatrica Inc Method for storing biological material in a dissolvable matrix
ES2812250T3 (es) 2005-11-28 2021-03-16 Marinus Pharmaceuticals Inc Formulaciones de ganaxolona y procedimientos para la preparación y uso de las mismas
GB2432528B (en) * 2005-11-29 2011-04-06 Ian Ripley Anti-viral compositions comprising flavanone glycosides and fruit acids
CA2645058C (en) * 2006-03-08 2013-07-30 Nihon Nohyaku Co., Ltd. Pharmaceutical composition for external use
CA2645110C (en) 2006-03-08 2013-11-19 Nihon Nohyaku Co., Ltd. Pharmaceutical composition for external use
JP5160409B2 (ja) * 2006-03-08 2013-03-13 日本農薬株式会社 外用の医薬組成物
US8431140B2 (en) * 2006-06-14 2013-04-30 Dr. Reddy's Laboratories, Inc. Topical compositions
SI2530083T1 (sl) 2006-09-22 2016-09-30 Pharmacyclics Llc Inhibitorji Bruton tirozin kinaze
KR100721126B1 (ko) 2006-12-28 2007-05-23 (주)바이오앤에이치엔티 모기 기피제 조성물
EP2191827B1 (en) 2007-09-05 2013-10-30 Pola Pharma Inc. Antifungal composition
US20100204293A1 (en) * 2007-09-05 2010-08-12 Pola Pharma Inc. Pharmaceutical composition
WO2009031644A1 (ja) * 2007-09-05 2009-03-12 Pola Pharma Inc. 抗真菌医薬組成物
EP2200607A4 (en) 2007-09-10 2012-02-22 Calcimedica Inc COMPOUNDS MODULATING INTRACELLULAR CALCIUM
JP5421901B2 (ja) * 2008-03-31 2014-02-19 国立大学法人広島大学 エンテロウイルス属の非エンベロープウイルスに対する抗ウイルス剤および抗ウイルス用組成物
GB2462022B (en) 2008-06-16 2011-05-25 Biovascular Inc Controlled release compositions of agents that reduce circulating levels of platelets and methods thereof
BRPI0917719A2 (pt) 2008-08-27 2019-11-19 Calcimedica Inc compostos que modulam cálcio intracelular
UA105375C2 (uk) 2009-01-09 2014-05-12 Егіш Дьйодьсердьяр Нільваношан Мюкеде Ресвеньтаршашаг Спосіб виготовлення вагінального супозиторія
CA2752557A1 (en) * 2009-02-13 2010-08-19 Topica Pharmaceuticals, Inc. Anti-fungal formulation
WO2010117089A2 (en) 2009-04-09 2010-10-14 Pola Pharma Inc. Antimycotic pharmaceutical composition
WO2010117091A2 (en) 2009-04-09 2010-10-14 Pola Pharma Inc. Antimycotic pharmaceutical composition
JP5635075B2 (ja) 2009-08-25 2014-12-03 株式会社ポーラファルマ 抗真菌医薬組成物
US7741330B1 (en) 2009-10-12 2010-06-22 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
ES2602475T3 (es) 2010-04-15 2017-02-21 Tracon Pharmaceuticals, Inc. Potenciación de la actividad anticáncer por terapia de combinación con inhibidores de la vía BER
US8754219B2 (en) 2010-04-27 2014-06-17 Calcimedica, Inc. Compounds that modulate intracellular calcium
PT2563776T (pt) 2010-04-27 2016-09-19 Calcimedica Inc Compostos que modulam o cálcio intracelular
WO2012018638A2 (en) 2010-07-26 2012-02-09 Biomatrica, Inc. Compositions for stabilizing dna, rna and proteins in blood and other biological samples during shipping and storage at ambient temperatures
EP2598661B1 (en) 2010-07-26 2017-09-27 Biomatrica, INC. Compositions for stabilizing dna, rna and proteins in saliva and other biological samples during shipping and storage at ambient temperatures
MX337711B (es) 2010-08-27 2016-03-15 Calcimedica Inc Compuestos que modulan el calcio intracelular.
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
US9512116B2 (en) 2012-10-12 2016-12-06 Calcimedica, Inc. Compounds that modulate intracellular calcium
EP3249054A1 (en) 2012-12-20 2017-11-29 Biomatrica, INC. Formulations and methods for stabilizing pcr reagents
WO2015054283A1 (en) 2013-10-08 2015-04-16 Calcimedica, Inc. Compounds that modulate intracellular calcium
KR20160093675A (ko) 2013-12-05 2016-08-08 파마싸이클릭스 엘엘씨 브루톤 티로신 키나제의 억제제
ES2762806T3 (es) 2014-02-10 2020-05-25 Respivant Sciences Gmbh Tratamiento utilizando estabilizadores de mastocitos para trastornos sistémicos
CA2938996A1 (en) 2014-02-10 2015-08-13 Patara Pharma, LLC Methods for the treatment of lung diseases with mast cell stabilizers
EP3134418A4 (en) 2014-04-23 2018-01-03 The Research Foundation for The State University of New York A rapid and efficient bioorthogonal ligation reaction and boron-containing heterocycles useful in conjuction therewith
CN113826612B (zh) 2014-06-10 2022-11-22 生物马特里卡公司 在环境温度下稳定凝血细胞
US9839644B2 (en) 2014-09-09 2017-12-12 ARKAY Therapeutics, LLC Formulations and methods for treatment of metabolic syndrome
US9359316B1 (en) 2014-11-25 2016-06-07 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
US10227333B2 (en) 2015-02-11 2019-03-12 Curtana Pharmaceuticals, Inc. Inhibition of OLIG2 activity
CA2977521C (en) 2015-02-27 2024-03-19 Curtana Pharmaceuticals, Inc. 1-(aryl)-3-(heteroaryl) urea compounds and their use as olig2 inhibitors
EP3331522A1 (en) 2015-08-07 2018-06-13 Patara Pharma LLC Methods for the treatment of mast cell related disorders with mast cell stabilizers
WO2017027402A1 (en) 2015-08-07 2017-02-16 Patara Pharma, LLC Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
AU2016368265B2 (en) 2015-12-08 2021-10-28 Biomatrica, Inc. Reduction of erythrocyte sedimentation rate
US10851123B2 (en) 2016-02-23 2020-12-01 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
ES2910787T3 (es) 2016-05-12 2022-05-13 Univ Michigan Regents Inhibidores de ASH1L y métodos de tratamiento con los mismos
US10821105B2 (en) 2016-05-25 2020-11-03 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists in combination with local anesthetics and vasoconstrictors for improved local anesthesia
WO2017205769A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017205762A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017205766A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
CN109843868A (zh) 2016-08-26 2019-06-04 科泰纳制药公司 Olig2活性的抑制
EP3506893A4 (en) 2016-08-31 2020-01-22 Respivant Sciences GmbH CROMOLYNE COMPOSITIONS FOR THE TREATMENT OF CHRONIC COUGH DUE TO IDIOPATHIC PULMONARY FIBROSIS
JP2019531308A (ja) 2016-10-07 2019-10-31 レシュピファント サイエンシス ゲゼルシャフト ミット ベシュレンクター ハフトゥングRespivant Sciences Gmbh 肺線維症の治療のためのクロモリン組成物
EP3706867A4 (en) 2017-11-07 2021-08-11 The Regents Of The University Of Michigan THERAPEUTIC COMBINATION FOR TREATMENT OF CEREBELLIC ATAXIA
CN111655257A (zh) 2017-11-10 2020-09-11 密歇根大学董事会 Ash1l抑制剂及用其进行治疗的方法
CA3084809A1 (en) 2017-12-07 2019-06-13 The Regents Of The University Of Michigan Nsd family inhibitors and methods of treatment therewith
US11685722B2 (en) 2018-02-28 2023-06-27 Curtana Pharmaceuticals, Inc. Inhibition of Olig2 activity
US11319302B2 (en) 2018-06-07 2022-05-03 The Regents Of The University Of Michigan PRC1 inhibitors and methods of treatment therewith
CN113166051A (zh) 2018-07-27 2021-07-23 同心镇痛药物公司 酚类trpv1激动剂的聚乙二醇化前药
GB2591681A (en) 2018-08-29 2021-08-04 Ftf Pharma Private Ltd Methotrexate pharmaceutical composition
US20200069742A1 (en) 2018-08-29 2020-03-05 Myos Rens Technology Inc. Methods for alleviating, inhibiting or reversing muscle disuse atrophy in mammals
US20200108102A1 (en) 2018-10-03 2020-04-09 Myos Rens Technology Inc. Spray dried follistatin product
WO2020085904A2 (en) 2018-10-24 2020-04-30 SeraNovo B.V. Deep eutectic solvent platform for oral pharmaceutical formulations
NL2021864B1 (en) * 2018-10-24 2020-05-13 Seranovo B V Deep Eutectic Solvent Platform for Oral Pharmaceutical Formulations
US10925904B2 (en) 2018-11-06 2021-02-23 Myos Rens Technology, Inc. Methods and compositions for improving skeletal muscle protein fractional synthetic rate
AU2019417833A1 (en) 2018-12-31 2021-06-24 Biomea Fusion, Inc. Irreversible inhibitors of menin-MLL interaction
WO2020160113A1 (en) 2019-02-01 2020-08-06 Myos Rens Technology Inc. Egg yolk powder for improving quality of life and increasing activity in aging and chronically ill mammals
EP3937938A1 (en) 2019-03-15 2022-01-19 Unicycive Therapeutics Inc. Nicorandil derivatives
JP2023533982A (ja) 2020-07-10 2023-08-07 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Gas41阻害剤及びその使用方法
CA3202151A1 (en) 2020-12-16 2022-06-23 Biomea Fusion, Inc. Fused pyrimidine compounds as inhibitors of menin-mll interaction
WO2023018825A1 (en) 2021-08-11 2023-02-16 Biomea Fusion, Inc. Covalent inhibitors of menin-mll interaction for diabetes mellitus
WO2023027966A1 (en) 2021-08-24 2023-03-02 Biomea Fusion, Inc. Pyrazine compounds as irreversible inhibitors of flt3
WO2023039240A1 (en) 2021-09-13 2023-03-16 Biomea Fusion, Inc. IRREVERSIBLE INHIBITORS OF KRas
WO2023086341A1 (en) 2021-11-09 2023-05-19 Biomea Fusion, Inc. Inhibitors of kras
US11945785B2 (en) 2021-12-30 2024-04-02 Biomea Fusion, Inc. Pyrazine compounds as inhibitors of FLT3
WO2023235618A1 (en) 2022-06-03 2023-12-07 Biomea Fusion, Inc. Fused pyrimidine compounds as inhibitors of menin

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US33221A (en) * 1861-09-03 Improvement in soap
US4151273A (en) * 1974-10-31 1979-04-24 The Regents Of The University Of California Increasing the absorption rate of insoluble drugs
USRE33221E (en) 1982-04-29 1990-05-22 American Dental Association Health Foundation Dental restorative cement pastes
US5389677B1 (en) * 1986-12-23 1997-07-15 Tristrata Inc Method of treating wrinkles using glycalic acid
EP0319988A1 (en) * 1987-12-09 1989-06-14 Showa Denko Kabushiki Kaisha External dermatological composition
US5215757A (en) * 1991-03-22 1993-06-01 The Procter & Gamble Company Encapsulated materials
US5162117A (en) * 1991-11-22 1992-11-10 Schering Corporation Controlled release flutamide composition
DK0617612T3 (da) * 1991-12-18 1998-04-14 Warner Lambert Co Fremgangsmåde til fremstilling af en fast dispersion
US5340591A (en) * 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine

Also Published As

Publication number Publication date
ES2118677T3 (es) 2001-10-16
EP0833611B1 (en) 2001-08-22
DK0833611T3 (da) 2001-10-08
EP0833611A1 (en) 1998-04-08
AU695622B2 (en) 1998-08-20
HK1008774A1 (en) 1999-05-21
PT833611E (pt) 2002-01-30
CA2225286C (en) 2003-06-10
AU6247396A (en) 1997-01-22
US6083518A (en) 2000-07-04
DE69614689D1 (de) 2001-09-27
DE833611T1 (de) 1999-01-07
ATE204466T1 (de) 2001-09-15
JPH11508250A (ja) 1999-07-21
CA2225286A1 (en) 1997-01-09
ES2118677T1 (es) 1998-10-01
DE69614689T2 (de) 2002-06-27
JP4020331B2 (ja) 2007-12-12
NZ311208A (en) 1999-03-29
WO1997000670A1 (en) 1997-01-09
ZA965237B (en) 1997-01-09

Similar Documents

Publication Publication Date Title
SE9502244D0 (sv) A composition and a process for the preparation thereof
NO964939D0 (no) Fremgangsmåte for fremstilling av virkestoffpreparater i form av en fast lösning av virkestoffet i en polymermatriks, samt virkestoffpreparater fremstilt ved hjelp av denne fremgangsmåte
FI103091B1 (sv) Förfarande för framställning av en sammansättning med fördröjd frigöring
MY121192A (en) New compounds.
ES2170813T3 (es) Acidos 2,2-dicloroalcanocarboxilicos, proceso para su preparacion, medicamentos que los contienen y su uso para tratar la resistencia a la insulina.
IS3966A (is) Aðferð til framleiðslu á lyfjablöndum sem innihalda nifedipine
NO973646D0 (no) Orale doseringsformer inneholdende et <beta>-laktam antibiotikum
ATE237316T1 (de) Ibuprofen und domperidone enthaltende pharmazeutische zusammensetzungen
SE9403389D0 (sv) Pharmaceutical composition containing derivattves of sex hormones
DE69416034T2 (de) Pharmazeutische Zubereitung zur rektalen Verabreichung von pharmakologisch wirksamen Verbindungen
ATE19472T1 (de) Verwendung von 5-phenyl-1,4-benzodoazepinen zur herstellung von analgetisch wirksamen pharmazeutischen zubereitungen.
EP0305194A3 (en) Veterinary composition
JPS57136503A (en) Expellent for noxious mollusk
GT198700016A (es) Procedimiento para la preparacion de n benzoil -n'-fenilu--reas.
IL117734A (en) Anellated beta-carbolines their preparation and pharmaceutical compositions containing them